{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=12", "query": { "condition": "Neuroectodermal Tumor", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 5012, "total_pages": 502, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T22:28:44.949Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02263508", "title": "Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 713, "start_date": "2014-12-08", "completion_date": "2021-03-11", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02263508" }, { "nct_id": "NCT07287917", "title": "Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin Cancer)", "HER2-low Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "AMXT 1501 Dicaprate", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2026-01-26", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 20, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287917" }, { "nct_id": "NCT00033293", "title": "Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Localized Resectable Neuroblastoma", "Localized Unresectable Neuroblastoma", "Regional Neuroblastoma", "Stage 4 Neuroblastoma", "Stage 4S Neuroblastoma" ], "interventions": [ { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Therapeutic Immune Globulin", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "8 Years", "sex": "ALL", "summary": "Up to 8 Years" }, "enrollment_count": 53, "start_date": "2004-03-15", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033293" }, { "nct_id": "NCT02039947", "title": "Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma and Brain Metastases" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2014-02-21", "completion_date": "2018-02-14", "has_results": true, "last_update_posted_date": "2019-05-21", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02039947" }, { "nct_id": "NCT00003173", "title": "High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Ovarian Cancer", "Retinoblastoma", "Testicular Germ Cell Tumor", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 36, "start_date": "1997-09", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2013-03-07", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003173" }, { "nct_id": "NCT01340729", "title": "Open-Label Study of TPI 287 for Patients With Metastatic Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "TPI 287", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 0, "start_date": "2013-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-05", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01340729" }, { "nct_id": "NCT04410445", "title": "Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma", "Melanoma Stage III", "Melanoma Stage IV", "Melanoma (Skin)" ], "interventions": [ { "name": "Bempegaldesleukin", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 765, "start_date": "2020-07-27", "completion_date": "2022-09-22", "has_results": true, "last_update_posted_date": "2023-04-21", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 62, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04410445" }, { "nct_id": "NCT03345095", "title": "A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "Marizomib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 749, "start_date": "2018-07-26", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Orange, California • San Francisco, California + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345095" }, { "nct_id": "NCT01009775", "title": "A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "YM155", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2009-11", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2015-09-04", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 12, "location_summary": "Mobile, Alabama • Tuscon, Arizona • Los Angeles, California + 6 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01009775" }, { "nct_id": "NCT00619112", "title": "Temozolomide in Treating Patients With Recurrent High-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Central Nervous System Neoplasm" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2007-10", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-10-22T22:28:44.949Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619112" } ] }